I don't really get the squabbling here. We need a trial(s). This forms the basis of a hypothesis, supported by the application on these two children and Sr agvhd data re safety and perhaps a supporting case of moa. Msb thought to give the market an update about it (not price sensitive) and good on them. All the relevant disclosures are there and the data is there. We continue to wait for updates.
Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics, page-136
-
- There are more pages in this discussion • 288 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
-0.025(2.10%) |
Mkt cap ! $1.330B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.22 | $1.15 | $6.344M | 5.404M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8683 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 32999 | 1 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |